Increased Use of Prophylactic Measures in Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Christina J. Sperna Weiland1,2, Megan M. L. Engels2, Alexander C. Poen3, Abha Bhalla4, Niels G. Venneman5, Jeanin E. van Hooft6, Marco J. Bruno7, Robert C. Verdonk8, Paul Fockens9, Joost P. H. Drenth1, Erwin J. M. van Geenen1, for the Dutch Pancreatitis Study Group

Received: 12 October 2020 / Accepted: 15 December 2020 / Published online: 25 February 2021
© The Author(s) 2021

Abstract
Background Nonsteroidal anti-inflammatory drugs (NSAIDs), pancreatic duct stenting, and intensive intravenous hydration have been proven to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. Trial participation and guideline changes demanded an assessment of the clinical practice of post-ERCP pancreatitis prophylaxis.

Aims The surveys aim to identify points of improvement to inform and educate ERCPists about current evidence-based practice.

Methods Two anonymous surveys were conducted among Dutch gastroenterologists in 2013 (n = 408) and 2020 (n = 575) for longitudinal views and attitudes pertaining to post-ERCP pancreatitis prophylaxis and recognition of post-ERCP pancreatitis risk factors.

Results In 2013 and 2020, respectively, 121 and 109 ERCPists responded. In the 2013 survey, 98% of them utilized NSAID prophylaxis and 62% pancreatic duct stent prophylaxis in specific cases. In the 2020 survey, the use of NSAIDs (100%), pancreatic duct stents (78%), and intensive intravenous hydration (33%) increased among ERCPists. NSAID prophylaxis was the preferred prophylactic measure for all risk factors in the 2020 survey, except for ampullectomy, pancreatic duct contrast injection, and pancreatic duct cannulation, for which NSAID prophylaxis and pancreatic duct stent combined was equally favored or preferred.

Conclusion Rectal NSAIDs are the most applied post-ERCP pancreatitis prophylaxis in the Netherlands, followed by pancreatic duct stents and intensive intravenous hydration. Additionally, there is reason to believe that recent guideline updates and active research participation have led to increased prophylaxis implementation.

Keywords ERCP · Pancreatitis · Gastroenterologists · Endoscopic retrograde cholangiopancreatography · Risk factors · Nonsteroidal anti-inflammatory agents · Surveys and questionnaires · Risk reduction behavior · Pancreatic ducts · Infusions · Intravenous
Abbreviations

ASGE American Society of Gastrointestinal Endoscopy
ERCP Endoscopic retrograde cholangiopancreatography
ESGE European Society of Gastrointestinal Endoscopy
IQR Interquartile range
IV Intravenous
NSAID Nonsteroidal anti-inflammatory drugs
NVGE Dutch Society of Gastroenterology
PD Pancreatic duct
SD Standard deviation

Introduction

Post-ERCP pancreatitis is the most common complication after an endoscopic retrograde cholangiopancreatography (ERCP) with an incidence range from 2.9 to 14.7% in unselected patient populations resulting in pancreatitis related mortality rate of up to 3% [1–3].

There is substantial evidence in favor of a number of effective prophylactic measures for preventing post-ERCP pancreatitis. Rectal nonsteroidal anti-inflammatory drugs (NSAIDs), pancreatic duct (PD) stenting, and intensive intravenous (IV) hydration are commonly accepted interventions that reduce the risk of this complication [4–6]. It is unclear whether a combination of these measures offers additive or even synergistic risk reduction beyond the protection conferred by the individual measures [7–10].

In 2013, we assessed the Dutch clinical practice using a nationwide survey among all ERCPists. This was instigated as a preparatory means to design a nationwide post-ERCP pancreatitis trial under the auspices of the Dutch Pancreatitis Study Group [9]. There have been multiple developments in the field following this survey. International guidelines have been adapted, particularly when it comes to post-ERCP pancreatitis prophylaxis [11–13]. Since 2010, the guideline of the European Society of Gastrointestinal Endoscopy (ESGE) recommends rectal NSAID administration for all patients without contraindication, whereas the 2017 guideline of the American Society of Gastrointestinal Endoscopy (ASGE) recommends rectal NSAIDs only for high-risk patients [12–14]. Both ESGE and ASGE guidelines recommend PD stent placement in high-risk patients. The 2019 ESGE guideline state that intensive IV hydration should be considered in patients with a contraindication to NSAIDs, whereas the ASGE guideline of 2017 suggests the use of intensive IV hydration whenever possible in a moderate to high-risk populations.

These changes from 2013 onward raise questions on the potential impact of guideline changes on Dutch gastroenterologists’ clinical practice. That is why we reassessed the clinical practice of post-ERCP pancreatitis prophylaxis in The Netherlands to identify potential points of improvement to inform and educate ERCPists about current evidence-based practice.

Methods

The survey was developed following the Declaration of Helsinki and using guidelines in the conduct of survey research [15]. The Medical Ethical Review Committee of the Radboudumc in Nijmegen, the Netherlands, approved this study and waived the need for informed consent. The study was registered in the online Netherlands Trial Registry (NL8493).

Study Setting

In the 2013 and 2020 surveys, the Dutch Society of Gastroenterology (NVGE) was consulted for all affiliated gastroenterologists, respectively, 408 and 575 for these 2 years. These account for 87% (2013) and 90% (2020) of the gastroenterologists registered in the Netherlands [16]. Gastroenterologists were eligible for participation if their current employment was in a community or academic center in the Netherlands and their institutional email address could be attained. For the 2020 survey, all endoscopy departments were separately consulted on whom of their gastroenterologists performed ERCPs (n = 219). Participation was voluntary and no incentives were offered for completion of the survey. The anonymity of participants was guaranteed.

The first survey was distributed as a postal survey from August to November 2013 to all affiliated gastroenterologists of the NVGE, no reminders were sent to non-responders. At that point in time, our research group was exclusively interested in the answers of ERCPists; hence, only their responses were recorded. The online survey was distributed by email between February 6th and March 18th, 2020. Two email reminders were sent with 2 weeks interval for an optimal response rate.

Survey Design

The 2013 survey was designed based on the content of the 2010 ESGE and 2012 ASGE guidelines concerning the clinical practice of post-ERCP pancreatitis prophylaxis (Fig. 1) [14, 17]. Three domains were constructed to investigate self-reported use of guideline-recommended prophylactic measures and factors influencing the decision to utilize them. The domains were as follows: respondent characteristics, post-ERCP pancreatitis prophylaxis use, and risk factor recognition (Supplementary Appendix 1). The international guidelines recommended rectal NSAIDs and prophylactic...
PD stenting at that time and thorough details on application and configuration of these prophylactic measures were included. The complete questionnaire consisted of 43 questions and the majority was compulsory and closed-ended formulated and came with a predetermined list of answer choices. Depending on the content of the question, one or multiple answers could be selected. When appropriate, open-ended questions or answer choices were offered for responses not anticipated from the survey design.

For the 2020 survey, the 2013 survey was adopted to an electronic format, containing similar domains and formatted in Google Forms (https://docs.google.com/forms). Both the ASGE 2017 and ESGE 2019 guidelines were consulted for additional recommendations relative to the 2013 survey (Fig. 1) [12, 13]. Most notably, intensive IV hydration was introduced as a prophylactic measure. Detailed questions on this prophylactic measure were therefore added to the 2020 survey. Additionally, one risk factor (previous pancreatitis) was removed due to concerns of its unambiguous interpretation caused by similarity to another risk factor. These amendments resulted in an updated survey containing 47 questions (Supplementary Appendix 2).

All gastroenterologists in the 2020 survey were required to fill in the respondent characteristics and risk factor recognition domains of each survey. ERCPists answered in-depth questions on the different prophylactic measures only when they indicated that they actually used that particular type of prophylaxis. All gastroenterologists in the 2020 survey were required to fill in the respondent characteristics and risk factor recognition domains of each survey. ERCPists answered in-depth questions on the different prophylactic measures only when they indicated that they actually used that particular type of prophylaxis.

The draft versions were piloted by a select group of five expert ERCPists. A consensus was formulated that a risk factor was sufficiently recognized if 85% or more of the respondents considered it as such. Their feedback was further implemented to improve on readability, content validity, and unambiguity of the questions.

**Statistical Analysis**

Categorical data were listed as frequency and percentage. Numeric data were assessed by mean with standard deviation (SD) or median with interquartile range (IQR). The Chi-squared test was used for comparison with the 2013 survey and subgroup analysis. All statistical analyses were conducted using SPSS, version 24, with statistical significance set at a two-sided alpha level of 5%. The difference in prophylaxis use between ERCPists in 2013 and 2020 was a predefined subgroup analysis.

**Results**

**Response**

Of the 408 gastroenterologists approached by mail in the 2013 survey, 121 (30%) ERCPists responded. The total number of ERCPists among approached gastroenterologists could not be discerned for the 2013 survey. The online survey administered in 2020 reached 548 of the 566 approached gastroenterologists. Of those reached, 161 gastroenterologists responded (29%). The response rate among currently practicing ERCPists was 50% (n = 109).

**Respondent Characteristics**

The characteristics of the respondents of the 2013 and the 2020 survey are listed in Table 1. Baseline characteristics did not significantly differ between surveys. In the 2020 survey, the mean age of the 161 respondents was 46 year and 116 (72%) were male. Twenty-five (16%) were employed...
in an academic center. Of the ERCPists, the mean practice time was 13.1 years, with a median lifetime exposure of 750 ERCPs.

**Pharmacological Prophylaxis**

In the 2013 survey, 98% \((n = 119)\) of the ERCPists used NSAID prophylaxis, of which 62% \((n = 73)\) in more than 80% of the ERCPs performed (Table 2, Supplementary Appendix Table S1). In comparison, all ERCPists in 2020 used NSAIDs prophylaxis. We found no rise in the percentage of ERCPists applying NSAID prophylaxis in comparison to the 2013 survey \((p = 0.18)\); however, there was a significant rise in the proportion of ERCPs in which prophylactic NSAIDs were used (respectively, 62% vs. 93%; \(p < 0.001\)).

Diclofenac was the preferred NSAID of choice and accounting for 95% in the 2020 survey. A dosage of 100 mg was used by 95% \( (n = 103) \) of the respondents and the drug was administered rectally by 98% \( (n = 107) \) of respondents. NSAID prophylaxis was administered prior to ERCP by 78% \( (n = 85) \) of the respondents.

**Prophylactic PD Stenting**

Prophylactic PD stenting was used by 62% \( (n = 75) \) in the 2013 survey versus 78% \( (n = 85) \) of the ERCPists in the 2020 survey \((p = 0.008, \text{Table 2})\). Of the 2013 PD stent users, 85% \( (n = 62) \) used PD stents in less than 20% of the ERCPs they performed versus 80% \( (n = 68) \) in 2020 \((p = 0.33)\).

Table 2 and Supplementary Appendix Table S2 show the responses with concerning (regularly used) stent configuration, diameter, length, shape, and flanges. In the 2020 survey, the majority \( (88%, n = 75) \) of the ERCPists checked stent dislocation through radiological imaging, 79% \( (n = 67) \) between 5 and 14 days. Given, a few \( (8%) \) respondents did indicate not checking for stent dislocation in the 2020 survey.

**Intensive IV Hydration**

The 2013 survey did not contain questions regarding intensive IV hydration. In the 2020 survey, intensive IV hydration was used by 33% \( (n = 36) \) (Table 2 and Supplementary Appendix Table S3). Lactated Ringer’s was the IV solution used by 31 respondents \( (86%) \). Fluid administration was most frequently in a maintenance dose \( (72%) \), and 39% reported bolus administration.

**Combination of Prophylaxis**

In 2020, the combination of rectal NSAID and PD stent prophylaxis was used more often compared to 2013, 69% \( (n = 75) \) versus 48% \( (n = 58) \) \((p = 0.002, \text{Table 2 and Supplementary Appendix Table S4})\). The percentage of procedures in which a combination of rectal NSAID and PD stent prophylaxis was used did not differ, 88% \( (n = 50) \) versus 79% \( (n = 59) \), respectively, in less than 20% of the procedures \((p = 0.24)\). The most cited motivation for this combination was the routine use of NSAID prophylaxis and PD stent placement in the case of repeated or deep guidewire insertion/contrast injection occurred during the ERCP.

The combination of rectal NSAIDs and intensive IV hydration was used by 34% \( (n = 37) \) of the 2020 ERCPists, of which 54% \( (n = 20) \) in less than 20% of the ERCPs performed and 27% \( (n = 10) \) in more than 80% of the ERCPs performed. The most cited reasons favoring the combination were maximal risk reduction for post-ERCP pancreatitis and utilization in high-risk patients and/or procedures.

**Risk Factor Recognition and Prophylaxis Use**

In the 2013 survey, 11 of the 18 scientifically well-established and recognized risk factors were identified by more than 85% of the ERCPists (Fig. 2, Supplementary Appendix Table S5). In 2020, eleven of the seventeen risk factors were identified as such. There were a few differences
Table 2  Prophylactic measures

|                        | ERCPists 2013 (n event/n total) | ERCPists 2020 (n = 109) | p value |
|------------------------|----------------------------------|-------------------------|---------|
| Use of NSAID prophylaxis—no. (%) | 119 (98)                         | 109 (100)               | 0.18    |
| Percentage of NSAID prophylaxisa—no. (%) |                                |                         | <0.001  |
| <20%                   | 8/116 (7)                        | 0                       |         |
| 20–40%                 | 8/116 (7)                        | 1 (1)                   |         |
| 41–60%                 | 9/116 (8)                        | 1 (1)                   |         |
| 61–80%                 | 18/116 (15)                      | 6 (6)                   |         |
| >80%                   | 73/116 (62)                      | 101 (93)                |         |
| Type NSAID preferreda—no. (%) |                                |                         |         |
| Diclofenac             | 115/119 (98)                     | 103 (95)                |         |
| Indomethacin           | 4/119 (3)                        | 6 (6)                   |         |
| Dosea—no. (%)          |                                  |                         |         |
| 50 mg                  | 10/99 (9)                        | 5 (5)                   |         |
| 80 mg                  | 1/99 (1)                         | 1 (1)                   |         |
| 100 mg                 | 86/99 (74)                       | 103 (95)                |         |
| 150 mg                 | 1/99 (1)                         | 0                       |         |
| 200 mg                 | 1/99 (1)                         | 0                       |         |
| Route of administrationa—no. (%) |                                |                         |         |
| Rectal                 | 117/118 (99.1)                   | 107 (98)                |         |
| Oral                   | 0                                | 1 (1)                   |         |
| Intravenous            | 0                                | 1 (1)                   |         |
| S.c./i.m.              | 1/118 (0.9)                      | 0                       |         |
| Timing of administrationa—no. (%) |                                |                         |         |
| Before ERCP            | 59/119 (50)                      | 85 (78)                 |         |
| After ERCP             | 60/119 (50)                      | 16 (15)                 |         |
| Differs per procedure  | NA                               | 8 (7)                   |         |
| Use of PD stent prophylaxis—no. (%) | 75 (62)                          | 85 (78)                 | 0.008   |
| Percentage of ERCPs PD stents are useda—no. (%) |          |                         | 0.33    |
| <20%                   | 62/73 (85)                       | 68 (80)                 |         |
| 20–40%                 | 10/73 (14)                       | 17 (20)                 |         |
| 41–60%                 | 1/73 (1)                         | 0                       |         |
| Stent diameter regularly useda—no. (%) |                                |                         |         |
| 3Fr                    | 7/75 (9)                         | 11 (13)                 |         |
| 5Fr                    | 67/75 (89)                       | 78 (92)                 |         |
| 7Fr                    | 11/75 (15)                       | 7 (8)                   |         |
| Dislocation controla—no. (%) |                                |                         |         |
| None                   | 15/74 (20)                       | 8 (9)                   |         |
| Radiology              | 54/74 (73)                       | 75 (88)                 |         |
| Endoscopy              | 1/74 (1)                         | 0                       |         |
| Both                   | 2/74 (3)                         | 2 (2)                   |         |
| Use of intensive IV hydration—no. (%) | NA                               | 36 (33)                 |         |
| Type of infusion fluida—no. (%) | NA                               |                         |         |
| Lactated Ringer’s      | 31 (86)                          | 5 (14)                  |         |
| Normal saline          |                                  |                         |         |
| Administration as a bolusa—no. (%) | NA                               | 14 (39)                 |         |
| Administration as a maintenancea—no. (%) | NA                               | 26 (72)                 |         |
| Use of NSAID + stent prophylaxis—no. (%) | 58/119 (48)                      | 75 (69)                 | 0.002   |
| Use of NSAID + hydration prophylaxis—no. (%) | NA                               | 37 (34)                 |         |

ERCP endoscopic retrograde cholangiopancreatography, NSAID nonsteroidal anti-inflammatory drugs, mg milligram, s.c subcutaneously, i.m. intramuscular, PD pancreatic duct, IV intravenous, Fr French, NA not applicable
p values ≤ 0.05 (bold) are statistically significant (Chi-squared test)
aPercentage of respondents who answered specific question
in risk factors identified by the ERCPists in 2013 compared to 2020: balloon dilatation of the papilla was identified by more than 85% and non-dilated extrahepatic bile duct system by less than 85% of the 2020 ERCPists. Three of the risk factors (earlier post-ERCP pancreatitis, non-dilated extrahepatic bile duct system, and normal bilirubin) were categorized as risk factors less frequent by the 2020 respondents in comparison to the 2013 respondents ($p = 0.048$, $p = 0.002$, $p = 0.001$, respectively). Absence of chronic pancreatitis, PD cannulation, and difficult cannulation were categorized as risk factors more often by the 2020 respondents $p = 0.005$, $p = 0.001$ and $p = 0.004$, respectively.

In the 2013 survey, ampullectomy was seen as the only risk factor that warranted a combination of rectal NSAID and PD stent in more than a third ($n = 33$) of respondents (34%, Supplementary Appendix Table S6). The ERCPists stated in 2020 that NSAID prophylaxis was the preferred prophylaxis for 14 of the risk factors (83%). In the case of ampullectomy or PD contrast injection, a similar proportion of ERCPists elected NSAID prophylaxis or combination of NSAID and PD stent prophylaxis (respectively, 38% and 39%). If the PD was cannulated, some 50% chose the combination, while 34% relied on NSAID prophylaxis.

Eighty-three percent of the 2013 ERCPists indicated the presence of a post-ERCP pancreatitis prophylaxis protocol in their center compared to 84% ($n = 92$) in 2020 (Supplementary Appendix Table S7). Of the respondents in 2020 who indicated that a protocol was present, NSAID prophylaxis was included in nearly 100%, PD stent prophylaxis in 31% in the 2013 survey, and 24%. Intensive IV hydration was present in 38% of the protocols in 2020.

**Discussion**

Rectal NSAID is the most frequently used prophylaxis to prevent post-ERCP pancreatitis in the Netherlands and is applied by all ERCPists that responded to the 2020 survey.
A steep rise in NSAID prophylaxis was observed from 2013 to 2020, exemplified by an increase from 62 to 93% of the respondents in more than 80% of ERCPs. Prophylactic PD stent placement was used in selected cases by 78% of ERCPists in 2020, significantly more than in 2013. One-third of the surveyed ERCPists in 2020 acknowledged the use of intensive IV hydration. Currently, exclusive use of NSAIDs was the preferred prophylactic measure, except for ampullectomy, PD contrast injection, and PD cannulation, in which the combination of NSAID prophylaxis and PD stent was equally favored or preferred.

In 2010 and 2012, two European surveys targeting ERCPists reported 16% and 35% use of rectal NSAID, respectively [18, 19]. The results of a landmark trial published months after the 2012 survey was conducted, demonstrating a significant decrease in post-ERCP pancreatitis due to the use of rectal NSAIDs. Their use as post-ERCP pancreatitis prophylaxis became more common practice, as demonstrated by our already high 98% NSAID use rate among ERCPists in 2013. The high percentage might be attributed to ease of use and negligible costs in certain countries [20]. The favored timing (before ERCP), route (rectal), and dosage (100 mg) were answered more frequently by the 2020 respondents. The shift in answers toward these recommended administration methods in the 2020 survey could be explained by our first survey, predating more recent administration recommendations (Table 3).

It is unclear why only 78% of the ERCPists in 2020 agree with the indication of PD stent placement, as it is regarded as an evidence-based prophylactic strategy [5, 21]. Several surveys have reported considerable practice variation in prophylactic PD stent use ranging from 53 to 96% [18, 19, 22]. Given that extra manipulation of the PD increases the likelihood of post-ERCP pancreatitis, PD stent placement

### Table 3 European and American Society of Gastrointestinal Endoscopy guideline overview

| Guideline | Rectal NSAID | PD stent | Hydration |
|-----------|--------------|----------|-----------|
| 2010 ESGE | Diclofenac/indomethacin | High-risk patients | NA |
| Rectal    | 100 mg       | 5-Fr     | Short     |
| Before or after ERCP | 5–10 days evaluation of stent dislocation, otherwise endoscopic removal of retained stents | |
| 2014 ESGE | Diclofenac/indomethacin | High-risk patients | NA |
| Rectal    | 100 mg       | 5-Fr     | Short     |
| Before or after ERCP | 5–10 days evaluation of stent dislocation, otherwise endoscopic removal of retained stents | |
| All patients without contraindications | |
| 2019 ESGE | Diclofenac/indomethacin | High-risk patients | Aggressive hydration |
| Rectal    | 100 mg       | Defined as inadvertent guidewire insertion/opacification of PD, double guidewire cannulation | Lactated Ringer’s solution |
| Immediately before ERCP | 5-Fr | When feasible |
| All patients without contraindications | No internal flanges | |
| 2012 ASGE | Indomethacin/diclofenac | High-risk patients | NA |
| Rectal    | Before ERCP or upon arrival in recovery room | Defined as SOD, manometry, ampullectomy, pancreatic sphincterotomy, precut sphincterotomy, pancreatic brush cytology, difficult biliary cannulation, and manipulation of the PD with wires | |
| 2017 ASGE | Indomethacin/diclofenac | High-risk individuals | Periprocedural |
| Rectal    | Before ERCP or upon arrival in recovery room | Suggestion that it may reduce risk and severity in average-risk individuals | Lactated Ringer’s solution |

**ESGE** European Society of Gastrointestinal Endoscopy, **ASGE** American Society of Gastrointestinal Endoscopy, **ERCP** endoscopic retrograde cholangiopancreatography, **NSAID** nonsteroidal anti-inflammatory drugs, **PD** pancreatic duct, **Fr** French, **NA** not applicable
is not without risk [23], and the risk rises further if placement fails [24]. A 2011 survey among US gastroenterologists showed low-volume ERCPists (< 50 ERCPs/year) feel less comfortable with pancreatic duct stenting, providing a potential explanation for this discrepancy [25]. With respect to stent configuration, the best consensus in the 2020 survey was reached for diameter, with 92% using 5Fr. The flange options “internal” or “external and internal” were given by 14/89 times by 2020 respondents, despite current guidelines arguing internal flanges can impede spontaneous dislodgement [13, 26].

While each prophylactic measure confers protection on its own, their combined effect has not been confirmed by current literature. ERCPists in our 2020 survey did demonstrate consensus on applying NSAID and PD stent prophylaxis in high-risk patients with (inadvertent) PD cannulation. The additional benefit of this combination in high-risk patients is expected to follow from a multicenter randomized controlled trial [10]. Considering intensive IV hydration, a relatively small percentage of ERCPists reported using this prophylactic measure in our 2020 survey compared to 83% in a 2018 North American survey [27]. Intensive IV hydration may perhaps be the preferred prophylactic measure in North America given the elevated price of the composite rectal indomethacin in certain countries [28, 29]. Despite a network meta-analysis suggesting this combination yields the lowest post-ERCP pancreatitis incidence [30], the future results of another multicenter randomized controlled trial will provide additional clarification [9].

The risk factor recognition of surveyed endoscopists must be interpreted with caution. The most recent international guidelines are not consistent on the contribution of each individual patient- or procedure-related risk factor for the development of post-ERCP pancreatitis, such as a non-dilated extrahepatic bile duct system [12, 13]. Each risk factor’s weight has been determined by a limited number of studies with varying quality of evidence, often predating the implementation of routine NSAID prophylaxis [29, 31].

The promising results from initial pilot studies on post-ERCP pancreatitis prophylactic measures prompted multiple large-scale trials to verify their effectiveness (Fig. 1). The results have led to guidelines becoming more specific on which patients benefit most from the various prophylactic measures [12, 13]. In the Netherlands, multicenter trials of the Dutch Pancreatitis Study Group have been designed with the input of ERCPists. These trials contribute to their knowledge base and the implementation of evidence-based practice. Additionally, the implementation of a national endoscopic complication registry in 2009 has led to more awareness for post-ERCP pancreatitis and usages of potential prophylactic methods. The mandatory complication meetings, discussing individual cases of post-ERCP pancreatitis with quality improvement goals, have contributed to an increased interest in novel prophylactic measures [32, 33].

A strength of this study is its high response rate among ERCPists, which is concurrent with other surveys among gastroenterologists [18, 19, 27]. This attributed to a valuable insight into the opinions and attitudes of ERCPists with regard to the use of post-ERCP prophylaxis in the Netherlands over time. Secondly, this has been the first survey conducted since the publication of the current ESGE guideline 1 year ago [13]. The questions on the various prophylactic methods were detailed, which resulted not only in an indication of the frequency of use, but also in which manner and with what motivation these methods were applied. The process of survey design was meticulous, with questions based on the most recent guidelines. Lastly, although the prophylaxis use and risk factor recognition captured by this survey may differ for other regions of the world, we can cautiously extrapolate our results to the European clinical practice given the use of the same guidelines. Thereby, our survey can shed insight into where there are differences, and we hopefully ignite international debate on best practices for preventing post-ERCP pancreatitis.

A limitation of the current study was the lack of data on actual post-ERCP pancreatitis rates of the surveyed ERCPists. The goal of our study was to capture the nationwide clinical practice and not investigate prophylactic measures set off against risk factors, justifying our methodology. Response bias could be introduced in our survey due to the possibility that ERCPists interested in reducing post-ERCP pancreatitis rates responded more often. Recall bias is an inherent limitation of survey sampling, where responses cannot directly be considered reflective of the general practice, as demonstrated in a recent retrospective review of electronic health databases [34].

In conclusion, our most recent survey demonstrated a 100% self-reported use of rectal NSAIDs administration among ERCPists. Significantly more ERCPists place PD stents than in 2013 and intensive IV hydration has come to the stage as a novel prophylactic measure in the clinical practice. In conjunction, this survey reveals the remaining improvements to be made. Recent guideline updates and active research participation have potentially led to this increased prophylaxis implementation.

Supplementary Information The online version of this article (https://doi.org/10.1007/s10620-020-06796-0) contains supplementary material, which is available to authorized users.

Acknowledgments CSW and ME designed the study protocol and questionnaire. RV, JvH, MB, JD, and EvG critically edited the survey questions. CSW and ME collected and analyzed the data and drafted the manuscript under supervision of JD and EvG. All co-authors read, edited, and approved the final manuscript.
**Funding** The study was funded by the Netherlands Organization for Health Research and Development (ZonMw, Grant No. 837001506) and the Radboud University Medical Center. ZonMw had no role in study design, data collection, data analysis, data interpretation, or preparation of the report. The corresponding author has full access to all the data in the study and bears final responsibility for the decision to submit for publication.

**Compliance with Ethical Standards**

**Conflict of interest** Christina J. Sperna Weiland, Megan M.L. Engels, Robert C. Verdonk, Alexander C. Poen, Abha Bhalla, and Niels G. Venneman do not have potential conflicts of interest or disclosures to report. Jeanin E. van Hooft has received research support from Cook Medical and received consultancy fees from Medtronic, Cook Medical, and Boston Scientific. Marco J. Bruno has received research support from Boston Scientific, Cook Medical, Pentax Medical, International, and Boston Scientific. Marco J. Bruno has received research support from Gilead to support Hepatitis C elimination in The Netherlands. Erwin J.M. van Geemen has received research support from Mylan and Olympus and acted as a consultant for MTV-Endoskopie.

**Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

**References**

1. Andriulli A, Loperfido S, Napolitano G, et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. *Am J Gastroenterol*. 2007;102:1781–1788.
2. Kochar B, Akshintala VS, Afghani E, et al. Incidence, severity, and mortality of post-ERCP pancreatitis: a systematic review by using randomized, controlled trials. *Gastrointest Endosc*. 2015;81:143.e9–149.e9.
3. Smeets XJNM, Bouhouch N, Buxbaum J, et al. The revised Atlanta criteria more accurately reflect severity of post-ERCP pancreatitis compared to the consensus criteria. *United Eur Gastroenterol J*. 2019;7:557–564.
4. Serrano J, de Moura D, Bernardo W, et al. Nonsteroidal anti-inflammatory drugs versus placebo for post-endooscopic retrograde cholangiopancreatography pancreatitis: a systematic review and meta-analysis. *Endosc Int Open*. 2019;07:E477–E486.
5. Sugimoto M, Takagi T, Suzuki R, et al. Pancreatic stents to prevent post-endooscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis. *World J Meta-Anal*. 2019;7:249–258.
6. Zhang ZF, Duan ZJ, Wang LX, Zhao G, Deng WG. Aggressive hydration with lactated ringer solution in prevention of postendoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials. *J Clin Gastroenterol*. 2017;51:e17–e26.
7. Hajalikhani M, Emami MH, Khodadoostan M, et al. Combination of diclofenac and aggressive hydration for the prevention of post-ERCP pancreatitis. *Gastroenterol Hepatol Bed Bench*. 2018;11:319–324.
8. Hosseini M, Shalchiantabrizi P, Yektaroudy K, Dadgar-moghaddam M, Salari M. Prophylactic effect of rectal indomethacin administration, with and without intravenous hydration, on development of endoscopic retrograde cholangiopancreatography pancreatitis episodes: a randomized clinical trial. *Arch Iran Med*. 2016;19:538–543.
9. Smeets XJNM, da Costa DW, Fockens P, et al. Fluid hydration to prevent post-ERCP pancreatitis in an average- to high-risk patients receiving prophylactic rectal NSAIDs (FLUYT trial); study protocol for a randomized controlled trial. *Trials*. 2018;19:1–9.
10. Elmunzer BJ, Serrano J, Chak A, et al. Rectal indomethacin alone versus indomethacin and prophylactic pancreatic stent placement for preventing pancreatitis after ERCP: study protocol for a randomized controlled trial. *Trials*. 2016;17:1–6.
11. Dumonceau JM, Andriulli A, Elmunzer BJ, et al. Prophylaxis of post-ERCP pancreatitis: European society of gastrointestinal endoscopy (ESGE) guideline—updated June 2014. *Endoscopy*. 2014;46:799–815.
12. Chandrasekharva H, Khashab MA, Muthusamy VR, et al. Adverse events associated with ERCP. *Gastrointest Endosc*. 2017;85:32–47.
13. Dumonceau JM, Kapral C, Aabakken L, et al. ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy* 2020;52:127–149.
14. Dumonceau JM, Andriulli A, Deviere J, et al. European Society of Gastrointestinal Endoscopy (ESGE) Guideline: prophylaxis of post-ERCP pancreatitis. *Endoscopy*. 2010;42:503–515.
15. Kelley K, Clark B, Brown V, Sitzia J. Good practice in the conduct and reporting of survey research. *Int J Qual Heal Care*. 2003;15:261–266.
16. KNMG. Aantal geregistreerde specialisten/profielartsen op peildatum 31 December van het jaar. 2018. https://www.knmg.nl/web/file?uuid=ffd10764-12d9-48aa-8514-2df93e523e21&owner =5e945405-d6ca-4deb-aa16-7a2f088aa173&contentid=70724 &elementid=2112442. Accessed 28 Jun 2020.
17. Anderson MA, Fisher L, Jain R, et al. ASGE guideline: complications of ERCP. *Gastrointest Endosc*. 2012;75:467–473.
18. Dumonceau JM, Rigaux J, Kahaleh M, et al. Prophylaxis of post-ERCP pancreatitis: a practice survey. *Gastrointest Endosc*. 2010;71:934.e2–934.e2.
19. Hanna MS, Portal AJ, Dhanda AD, Przemioslo R. UK wide survey on the prevention of post-ERCP pancreatitis. *Frontline Gastroenterol Hepatol*. 2007;5:1354–1365.
20. Zorginstituut Nederland. Medicijnkosten.nl Diclofenac 100 mg suppository 2020. https://www.medicijnkosten.nl/zoeken?trefwoord=Diclofenac&orig-trefwoord=Diclofenac&vorm=ZETPI&sterkte=100MG. Accessed 1 Jun 2020.
21. Freeman ML. Pancreatic stents for prevention of post-endooscopic retrograde cholangiopancreatography pancreatitis. *Clin Gastroenterol Hepatol*. 2007;5:1354–1365.
22. Brackbill S, Young S, Schoenfeld P, Elta G. A survey of physician practices on prophylactic pancreatic stents. *Gastrointest Endosc*. 2006;64:45–52.
23. Choksi NS, Fogel EL, Cote GA, et al. The risk of post-ERCP pancreatitis and the protective effect of rectal indomethacin in cases of attempted but unsuccessful prophylactic pancreatic stent placement. *Gastrointest Endosc*. 2015;81:150–155.
24. Sakai Y. Clinical usefulness and current problems of pancreatic duct stenting for preventing post-ERCP pancreatitis. *World J Clin Cases*. 2014;2:426.
25. Coté GA, Keswani RN, Jackson T, et al. Individual and practice differences among physicians who perform ERCP at varying
frequency: a national survey. Gastrointest Endosc. 2011;74:65.e12–73.e12.

26. He Q, Wang L, Peng C, et al. Modified prophylactic 5-fr pancreatic duct stent enhances the rate of spontaneous dislodgement: a multicenter randomized controlled trial. United Eur Gastroenterol J. 2018;6:1519–1526.

27. Avila P, Holmes I, Kouanda A, Arain M, Dai SC. Practice patterns of post-ERCP pancreatitis prophylaxis techniques in the United States: a survey of advanced endoscopists. Gastrointest Endosc. 2020;91:568–573.

28. Storm AC, Abu Dayyeh BK, Petersen BT, et al. Indomethacin for post-ERCP pancreatitis: prophylaxis at what cost? Gastrointest Endosc. 2020;91:207–208.

29. Elmunzer BJ, Hernandez I, Gellad WF. The skyrocketing cost of rectal indomethacin. JAMA Intern Med. 2020;180:631.

30. Njei B, McCarty TR, Muniraj T, et al. Comparative effectiveness of pharmacologic and endoscopic interventions for prevention of post-ERCP pancreatitis: a network meta-analysis. Endosc Int Open. 2020;8:E29–E40.

31. Li GZ, Wang F, Fang J, Zha HL, Zhao Q. Risk factors for post-endoscopic retrograde cholangiopancreatography pancreatitis: evidence from 1786 cases. Med Sci Monit. 2018;24:8544–8552.

32. Valori R, Senore C, de Lange TI, et al. Performance measures for endoscopy services: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative ESGE Quality Improvement Committee (QIC) Endoscopy Service Working Group. Endoscopy. 2018;50:1186–1204.

33. Ekkelenkamp VE, De Man RA, Ter Borg F, et al. Prospective evaluation of ERCP performance: results of a nationwide quality registry. Endoscopy. 2015;101:503–507.

34. Smith ZL, Elmunzer BJ, Cooper GS, Chak A. Real-world practice patterns in the era of rectal indomethacin for prophylaxis against post-ERCP pancreatitis in a high-risk cohort. Am J Gastroenterol. 2020;115:1.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.